Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.021x

Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has a cash flow conversion efficiency ratio of -0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-21.56 Million ≈ $-3.15 Million USD) by net assets (CN¥1.03 Billion ≈ $151.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cheng Du Sheng Nuo Biotec Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Cheng Du Sheng Nuo Biotec Co. Ltd. A for a breakdown of total debt and financial obligations.

Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
JOST Werke AG
XETRA:JST
0.081x
Xinjiang Yilite Industry Co Ltd
SHG:600197
-0.016x
Bergman & Beving AB (publ)
ST:BERG-B
0.065x
Macmic Science & Technology Co Ltd
SHG:688711
0.040x
Pason Systems Inc.
TO:PSI
0.061x
Grupo Posadas S.A.B. de C.V
MX:POSADASA
0.097x
Azenta Inc
NASDAQ:AZTA
0.012x
Sanofi India Limited
NSE:SANOFI
0.194x

Annual Cash Flow Conversion Efficiency for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)

The table below shows the annual cash flow conversion efficiency of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 688117 market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥918.32 Million
≈ $134.38 Million
CN¥25.27 Million
≈ $3.70 Million
0.028x -72.01%
2023-12-31 CN¥880.10 Million
≈ $128.79 Million
CN¥86.53 Million
≈ $12.66 Million
0.098x -14.99%
2022-12-31 CN¥826.74 Million
≈ $120.98 Million
CN¥95.62 Million
≈ $13.99 Million
0.116x +73.26%
2021-12-31 CN¥785.14 Million
≈ $114.89 Million
CN¥52.41 Million
≈ $7.67 Million
0.067x -63.87%
2020-12-31 CN¥437.57 Million
≈ $64.03 Million
CN¥80.84 Million
≈ $11.83 Million
0.185x +124.95%
2019-12-31 CN¥376.46 Million
≈ $55.09 Million
CN¥30.92 Million
≈ $4.52 Million
0.082x -59.40%
2018-12-31 CN¥327.35 Million
≈ $47.90 Million
CN¥66.23 Million
≈ $9.69 Million
0.202x -16.00%
2017-12-31 CN¥241.74 Million
≈ $35.37 Million
CN¥58.22 Million
≈ $8.52 Million
0.241x --

About Cheng Du Sheng Nuo Biotec Co. Ltd. A

SHG:688117 China Drug Manufacturers - Specialty & Generic
Market Cap
$847.06 Million
CN¥5.79 Billion CNY
Market Cap Rank
#9944 Global
#2830 in China
Share Price
CN¥36.78
Change (1 day)
-1.68%
52-Week Range
CN¥30.60 - CN¥48.78
All Time High
CN¥48.78
About

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more